tbuckley/cabot-search huggingface dataset:
Comparison of two preliminary screening methods for obstructive sleep apnea hypoventilation syndrome
Authors: Xing-jing Li, Yu-lan Zhang, Peng Wang, Fang Shen, Hai-feng Wang
Journal: BMJ (2011)

Both the sleep apnea scale of sleep disorders questionnaire (SA-SDQ) and the Epworth sleepiness scale (ESS) were used to evaluate 25 patients with snoring and 125 patients with obstructive sleep apnea hypoventilation syndrome ( OSAHS), and scores were calculated and compared to the results of polysomnography ( PSG). Results showed that there was significant difference in scores of ESS and SA-SDQ, apnea hyponea index (AHI) and the minimal saturation of blood oxygen (LSpO2) at night between patients with OSAHS and those with snoring (P ＜ 0.05). Score of both ESS and SA-SDQ significantly correlated with AHI ( r = 0. 78 and r = 0. 66, respectively, P ＜ 0. 01 ) , i. e. , more severe of the condition, higher the scores. Score of ESS is highly consistent with clinical presentations in patients with OSAHS and can be used as preliminary screening for its diagnosis, however, use of SA-SDQ score is limited in diagnosing OSAHS due to its lower consistency.

Key words: 
Sleep apnea, obstructive;  Scale
Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility.
Authors: Jamie Nadine Bakkum-Gamez, Lisa Marinelli, David A. Ahlquist, Seth Slettedahl, Douglas W. Mahoney, William R. Taylor, Kelli Burger, Calise K. Berger, Karen A Doering, Maureen Lemens, Viji Shridhar, Hatim T. Allawi, Hannah Berg, Maria Giakoumopoulos, Michael W. Kaiser, J. Kenneth Schoolmeester, Sarah Kerr, Mark E. Sherman, John B. Kisiel
Journal: Journal of Clinical Oncology (2020)

6072 Background: Effective screening tests for ovarian cancer (OC) are lacking; most cases present at advanced stage and portend poor prognosis. DNA methylation is an early event in carcinogenesis and can be detected in blood plasma samples from cancer patients. In DNA extracted from tissues, we first discovered, then validated discriminant methylated DNA marker (MDM) candidates for OC and subsequently tested independent plasma from women with and without OC. Methods: For discovery, DNA from 67 frozen tissues (18 high grade serous (HGS), 18 endometrioid, 15 clear cell (CC), 6 mucinous OCs; 10 benign fallopian tube epithelium (FT); and 19 buffy coats from cancer-free women underwent reduced representation bisulfite sequencing (RRBS) to identify MDMs associated with OC. Candidate MDM selection was based on receiver operating characteristic (ROC) discrimination, methylation fold change, and low background methylation among controls. Blinded biological validation was performed using methylated specific PCR on DNA extracted from independent FFPE tissues from OCs (36 HGS, 22 endometrioid, 21 CC, and 14 mucinous) and 29 FT. Top performing MDMs in tissue were tested using long-probe quantitative amplified signal assays in independent pre-treatment plasma samples from women newly-diagnosed with OC and population-sampled healthy women. A random forest modeling analysis was performed to generate predictive probability of disease; results were 500-fold in silico cross-validated. Results: After RRBS discovery and biological validation, 33 MDMs showed marked methylation fold changes (10 to &gt; 1000) across all OC histologies vs FT. The top 11 MDMs ( GPRIN1, CDO1, SRC, SIM2, AGRN, FAIM2, CELF2, DSCR6, GYPC, CAPN2, BCAT1) were tested on plasma from 91 women with OC (76 (84%) HGS) and 91 without OC; the cross-validated 11-MDM panel highly discriminated OC from controls (96% (95%CI 89-99%) specificity; 79% (69-87%) sensitivity, and AUC 0.91 (0.86 - 0.96)). Among HGS, the panel correctly identified 83%, including 5/6 stage I/II, and the majority of other subtypes (Table). Conclusions: Whole methylome sequencing, stringent filtering criteria, and biological validation yielded outstanding candidate MDMs for OC that performed with promisingly high sensitivity and specificity in plasma. Larger plasma-based OC MDM testing studies, with larger numbers of non-HGS histologies are warranted. [Table: see text]
Piperacillin To Prevent Cholangitis after Endoscopic Retrograde Cholangiopancreatography
Authors: Sven J. van den Hazel, Peter Speelman, Jacob Dankert, Kees Huibregtse, Guido N.J. Tytgat, Dirk J. van Leeuwen
Journal: Annals of Internal Medicine (1996)

Background: Cholangitis does not often occur after endoscopic retrograde cholangiopancreatography (ERCP), but it can be a serious complication of this procedure. Antibiotic prophylaxis is therefore...
吻合器痔上黏膜钉合术治疗痔进展
Authors: 姚礼庆, 钟芸诗
Journal: BMJ (2005)

痔是肛垫病理性肥大、下移和肛周皮下血管丛血流淤滞形成的团块,若伴有出血、脱垂等症状则称为痔[1].20世纪70年代以来,人们对痔有了更深入的认识,尤其是1998年意大利Palermo大学的Longo医生首先用吻合器痔上黏膜钉合术(procedure for prolapse and hemorrhoids, PPH术)治疗痔,开创了痔治疗的新纪元.我国自2000年7月引进PPH术以来,已治疗痔患者近30 000例,作者采用PPH术治疗500余例,疗效满意[2]。
Outcome of patients with breast cancer and a germline <i>BRCA</i> mutation in a prospective cohort.
Authors: Banu Arun, Angelica Gutierrez Barrera, Rachel M. Layman, Stephen K. Gruschkus, Isabelle Bedrosian, Constance T. Albarracin, Carlos Hernando Barcenas, Vicente Valero, Jennifer Keating Litton, Debu Tripathy
Journal: Journal of Clinical Oncology (2020)

1544 Background: There are limited large prospective single institution studies on outcome of breast cancer in patients with germline BRCA1 and BRCA2 mutation. The primary aim of this study was to determine the effect of a germline BRCA1 or BRCA2 mutation on recurrence-free survival (RFS) and overall survival (OS) in patients with breast cancer. Methods: This is a prospective cohort study of patients with invasive breast cancer recruited from the UT MD Anderson Cancer Center Breast Medical Oncology and Clinical Cancer Genetics Center. For the purpose of this analysis, newly diagnosed breast cancer patients who have had germline BRCA1 and BRCA2 testing within 12 months were included. Clinical and pathological data, and data regarding outcomes were collected in this prospective cohort. The Kaplan-Meier method and corresponding log-rank test were used to estimate OS and RFS and to compare survival by mutation status. Results: Between 1996 and 2015, 3026 patients were recruited. Median age at diagnosis was 45 (19-87) years. A germline BRCA mutation was detected in 361 (11.9%) patients (207 with BRCA1, 154 with BRCA2). After a median follow-up time of 5.3 (0.04-20.7) years, 437 (14.4%) patients recurred and 340 (11.2%) were deceased. At median follow-up time 5 years, 79.3% of BRCA1, 91.4% of BRCA2 and 89.6% of BRCA negative patients were disease free; this difference was significant (p = 0.0001). Difference in OS between BRCA1/2-positive and BRCA-negative patients was also significant (p = 0.0001), with 81.2% of BRCA1, 93.4% of BRCA2 and 90% of BRCA negative patients being alive at 5 years. Amongst 600 patients with triple negative breast cancer (TNBC) patients, DFS and OS were not significantly different between the 3 groups. Of those patients diagnosed under 40 years (n = 937), RFS and OS was significantly different between 3 groups at 5 years (0.001 for RFS and OS); 75% BRCA1, 92% BRCA2 and 86% BRCA negative patients were disease free and 77% BRCA1, 94% BRCA2 and 88% BRCA negative patients were alive. Conclusions: Patients with BRCA1 or BRCA2 mutations have different survival outcomes. The prognosis of the first cancer needs to be taken into consideration when deciding for preventive surgeries to prevent second primary breast cancers in these patients. Furthermore, for BRCA1 mutation carriers more effective therapy strategies need to be evaluated to improve outcome.
How does social cognition shape enculturation?
Authors: John Michael, Leon de Bruin
Journal: Behavioral and Brain Sciences (2020)

Abstract Other people in our culture actively transform our behavioral dispositions and mental states by shaping them in various ways. In the following, we highlight three points which Veissière et al. may consider in leveraging their account to illuminate the dynamics by which this occurs, and in particular, to shed light on how social cognition supports, and is supported by, enculturation.
Juvenile granulosa cell tumor: An interim report from the international ovarian and testicular stromal tumor (OTST) registry.
Authors: Anne Harris, Alexander Nelson, David Watson, Paige Mallinger, Miranda Langford, Allen Stering, Farheen Turk, Deborah F. Billmire, Dominik T. Schneider, A. Lindsay Frazier, Louis P Dehner, Ashley Hill, Yoav H. Messinger, Kris Ann P Schultz
Journal: Journal of Clinical Oncology (2020)

6064 Background: Juvenile granulosa cell tumors (JGCT) are rare sex cord-stromal tumors which occur primarily in children and adolescents. Methods: All individuals or proxy caregivers provided informed consent/assent for participation in the International OTST Registry. Clinical data was collected. When available, pathology was centrally reviewed. Staging was evaluated using the International Federation of Gynecology and Obstetrics (FIGO) classification. Kaplan-Meier survival analyses and exact permutation tests were performed. Results: Forty-two individuals with ovarian JGCT were enrolled. Median age at diagnosis was 9 years (range 0-27). Most individuals had Stage I disease (Stage Ia=16; Stage Ib=1; Stage Ic=16). Seven individuals presented with higher stage (Stage II=2; Stage III=5). Stage was unknown for 2 individuals. Three-year overall survival (OS) was 88% (CI 77%, 100%) and event-free survival (EFS) was 69% (CI 54%, 88%). At median follow-up time of 25 months (range 0-416), 9 patients (Stage Ia=1, Stage Ic=5, Stage III=3) had recurrent disease. Use of post-operative adjuvant chemotherapy varied by stage and timing of rupture. Of those with Stage Ic JGCT, 2/7 with preoperative rupture and 3/9 with intraoperative rupture recurred. Among individuals with recurrence, median time to recurrence was 11.5 months (range 3-19). Four of 9 individuals with recurrence survived (no evidence of disease n=2; alive with disease n=2). All individuals who died presented with extrapelvic recurrence. Median time from recurrence to death was 10 months (range 2-53). In individuals with recurrence, advanced stage at diagnosis (HR 5.1; p-value 0.087) and recurrence outside the tumor bed (HR Infinity; p-value 0.048) were associated with inferior OS. Three-year OS for individuals with recurrence was 57% (CI 30%, 100%). Conclusions: Low stage JGCT is associated with a favorable prognosis, however, recurrence is associated with lower survival rate. Within this series, recurrences presented within 2 years of diagnosis. Novel strategies are needed to address recurrent and extrapelvic disease.
Improve, a community-based exercise intervention versus support group to improve functional and health outcomes among older African American and non-hispanic white breast cancer survivors from diverse socioeconomic backgrounds: Recruitment strategies and baseline characteristics.
Authors: Cynthia Owusu, Nora Nock, Paul F. Hergenroeder, Kris Austin, Beth Bennett, Stephen Cerne, Halle C. F. Moore, Jean Petkac, Mark D. Schluchter, KATHRYN H. SCHMITZ, Monica Webb-Hooper, Leonard Wimbley, Sarah Coccia, Caitlin Nagy, Nathan A. Berger
Journal: Journal of Clinical Oncology (2020)

e24052 Background: We conducted an exercise study to IMPROVE health outcomes in older breast cancer survivors (BCS) from diverse racial and socioeconomic backgrounds. Here, we report cohort recruitment strategies and baseline characteristics. Methods: ‘IMPROVE’ is a randomized trial, designed to evaluate a group-based exercise intervention compared to support group. Participants were ≥ 65 years, had stage I-III breast cancer and within five years of treatment completion. Enrollment target was 220 participants, 25% in each of four strata defined by race (AA versus Non-Hispanic Whites [NHW]) and SES (low vs. high). Participants were recruited through hospital-based tumor registries, the state tumor registry or direct referrals. Results: Between October 2016 and November 2019, 7487 patients were screened, 4790 were potentially eligible, 230 were consented and 213 randomized into the study. The Eligible-to-Randomization rates were 4.4% overall, and 84%, 8%, and 2% for recruitment utilizing direct referrals, hospital and state registries, respectively. Median age of the randomized cohort was 70 years (range: 65-88 years) and included 25% AA/Low SES, 20% AA/High SES, 19% NHW/Low SES and 36% NHW/High SES Older BCS. Compared with registry-eligible patients, directly referred patients were more likely to be AA vs. NHW (41% vs. 19%, p = 0.003) and to accept study participation (88% vs. 16%, p &lt; 0.0001). Conclusions: Direct referrals resulted in the highest recruitment yield and was the most effective strategy for recruiting AA patients. Behavioral intervention studies seeking to target older BCS from racial minority and SES disadvantaged backgrounds should focus on strategies that foster direct referrals to study participation. Clinical trial information: NCT02763228 .
Tumor genomic analysis for biomarker identification in a phase I trial of the Wee 1 inhibitor adavosertib (AZD1775).
Authors: Abdul Rafeh Naqash, Arjun Mittra, Geraldine Helen O'Sullivan Coyne, Li Chen, Biswajit Das, Shivaani Kummar, Khanh T Do, Ting-Chia Chang, Ashley Bruns, Lamin Juwara, Brandon Miller, Robert J. Kinders, Ralph E. Parchment, Larry V Rubinstein, Jiuping Jay Ji, Deborah Wilsker, Angie B Dull, James H. Doroshow, Alice P. Chen, Naoko Takebe
Journal: Journal of Clinical Oncology (2020)

3624 Background: Adavosertib, a first-in-class Wee1 kinase inhibitor, abrogates G2/M cell cycle arrest causing premature mitosis and DNA replication stress, yielding enhanced DNA damage. Here we report on potential biomarkers of response from tumor genomic analysis in patients (pts) with solid tumors treated with adavosertib. Methods: Adavosertib was administered once daily on days 1-5 and 8-12 of a 21-day cycle. RECIST 1.1 was used to evaluate clinical response. Paired tumor biopsies were obtained for RNASeq gene expression profiling (GEP) and for whole-exome sequencing (WES) to evaluate gene mutation and copy number amplification (CNA). Fold change (FC) was calculated to define gene overexpression. To identify the frequency of CNA and mRNA overexpression for the genomic biomarkers of interest, cBioPortal analysis using TCGA and MSK-IMPACT datasets was performed. Differential GEP analysis of tumor and paired normal tissue was performed using the gene expression profiling interactive analysis (GEPIA) interface (Tang et al. 2017). Results: Out of 35 pts evaluable for response, 6 (17%) had partial response (PR; 4 ovarian carcinoma [OVC], 2 endometrial carcinoma [EC]). The median duration of response was 5.2 months (range 4.0-23.1). Eighteen pts (51.4%) had stable disease. Genomic analysis of tumor biopsies was available for 9 pts; 7 of these pts were evaluable for response, and 3 had PR (2 OVC, 1 EC). WES revealed TP53 mutations in 6 pts (66.6%; 3 pts with PR, 2 with progressive disease,1 not evaluable). On WES, tumor Cyclin E1 ( CCNE1) CNA was present in 1 of 3 PR pts while tumors from all 3 PR samples showed relatively high CCNE1 expression by RNAseq (FC = 4.07). In the MSK-IMPACT 2017 dataset, CCNE1 CNA was identified in 1.8% of pts (194 of 10336); of which, OVC (10.3%) and EC (8.7%) had the highest incidence of CCNE1 CNAs. In separate tumor-specific (OVC, EC) TCGA datasets having CCNE1 overexpression and/or CNA, overlap in CCNE1 overexpression with CCNE1 CNA was 35.5% (OVC) and 25.2% (EC). Compared to normal ovarian/ endometrial tissues, GEPIA analysis revealed significantly higher CCNE1 mRNA expression in OVC (FC = 3.5) and EC (FC = 3.8). Conclusions: CCNE1alterations (overexpression and/or CNA) tend to be enriched in OVC and EC with a limited fraction showing both overexpression and CNA. Tumor genomic analysis of additional OVC and EC pts treated with adavosertib is required to determine whether CCNE1 mRNA overexpression, regardless of CCNE1 CNA, is a potential biomarker of response to this drug in these tumor types. Funded by NCI contract No. HHSN261200800001E. Clinical trial information: NCT01748825 .
Hormone replacement therapy on mammographic density among postmenopausal women
Authors: Wen-hui Deng, Yue Chen, Ji-xu Pan, Yi-yong Wu
Journal: BMJ (2011)

Objective To investigate effects of hormone replacement therapy with conjugated equine estrogen (CEE) in different doses combined with medroxyprogesterone acetate ( MPA) on mammographic density among postmenopausal women and its clinical significance. Methods Ninety eligible postmenopausal women were randomized into three groups with varied treatment continuously for one year, Croup A receiving 0.3 mg CEE with 2 mg MPA and caltrate 600 mg and vitamin D 125 U daily; Group B receiving 0. 625 mg CEE combined with 2 mg MPA and caltrate 600 mg with vitamin D 125 U daily; and Group C receiving caltrate 600 mg and vitamin D 125 U daily. Mammographic density was analyzed using Wolfe and semi-quantitative methods for all of them and compared each other one year after treatment, as well as mammographic density before and after treatment in Groups A and B. Results One year after treatment, mammogrphic density reached the highest in postmenopausal woman of Group B and the lowest in those of Group C, with significant difference among the three groups (P ＜ 0. 01) and between Groups A and C (P ＜ 0. 01) and between Groups B and C ( P ＜ 0. 05 ). Mammogrphic density with semi-quantitative method increased significantly in Group A ( P ＜ 0. 05 ) and Group B ( P ＜ 0. 01 ), respectively, after treatment as compared with that before it. Change in mammografic density before and after treatment was greater in Group B than that in Group A, but not reaching statistically significant level (P ＞ 0. 05). Conclusions Hormone replacement therapy can cause the increase of mammographic density in postmenopausal women, possibly in a dose-dependent pattern, which suggest that HRT has side effect on breast tissue and the lowest effective dose of estrogen should be selected in HRT. Mammographic density can be used as an indicator to monitor side effect of HRT on breast.

Key words: 
Estrogen replacement therapy;  Mammography;  Menopause
2019 年新型冠状病毒的应急处理: 对皮肤科的启示
Authors: J. Tao, Z. Song, L. Yang, C. Huang, A. Feng, X. Man
Journal: British Journal of Dermatology (2020)

自 2019 年 12 月首次出现病例以来,COVID‐19(一种冠状病毒)迅速成为大流行病。这篇来自中国的关于 COVID‐19 的快速论文(很快发表的论文)是由疫情中心武汉的皮肤科医生撰写的。 皮肤科的工作人员可能面临风险,因为他们没有常规的防护设备,皮肤损伤可能会间接传播病毒。这些作者根据这次和以前冠状病毒暴发的经验提出了预防措施。 为非紧急患者提供在线咨询减少了去科室就诊的患者数量。在医院和皮肤科的入口处,由护士引导分诊,以识别出可能患有 COVID‐19 的患者,将咳嗽或发烧的患者引导到特定的 COVID‐19 区域,如果发烧可能与皮肤病有关,则咨询皮肤科医生。 科室工作人员在问诊期间佩戴 N95 口罩并遵守手部卫生规定。只有在常规血液检测和胸部 CT 扫描排除 COVID‐19 的情况下,患者才能被收治到病房。分诊无法检测出没有症状但已被感染的患者,因此医院应该提供一个随时在线的专家团队,以讨论疑似或诊断为 COVID‐19 的住院患者,并根据需要将他们转诊给放射科、呼吸科或重症监护同事。 确诊病例按照当地政策进行治疗。COVID‐19 住院患者的皮肤病通常可以使用照片、电子邮件和电话会议进行远程诊断和治疗。如有必要,多学科团队(由来自不同专科的医务人员组成的小组)可以在隔离病房的清洁区域会面。如果皮肤科医生必须看到患者,则应该提前提供所有的记录,以最大限度地减少暴露时间。 有了这些预防措施,截至 2020 年 2 月 20 日,武汉市皮肤科没有发现感染患者。 本摘要涉及研究: 预防和控制 2019 年新型冠状病毒医院感染的应急管理: 对皮肤科的启示
PANasta Trial: Cattell Warren versus Blumgart techniques of pancreatico-jejunostomy following pancreato-duodenectomy—A double-blinded multi-centered trial, trial results.
Authors: Christopher Halloran, John P. Neoptolemos, Kellie Platt, Richard Jackson, Srikanth Reddy, Derek Oreilly, Andreas Prachalias, Daniel H. Palmer, Krishna Menon, Brian Davidson, Dhanny Gomez, Paula Ghaneh
Journal: Journal of Clinical Oncology (2020)

4619 Background: Pancreatic anastomosis failure following pancreatic head excision, for suspected pancreatic cancer, leads to longer recovery and failure to start or complete adjuvant chemotherapy. The aim of this study is to evaluate whether a Blumgart anastomosis (BA) reduces the post operative pancreatic fistula (POPF) rate compared to a more traditional Cattell-Warren anastomosis (CWA). Methods: Patients with suspected pancreatic cancer, undergoing elective pancreato-duodenectomy were randomized intra-operatively to either a BA or a CWA. Anastomoses were constructed according to prior agreed techniques and an operative manual describing key surgical steps. Quality control of these key steps and adherence to the arm of randomization was ensured by operative photographs. Surgical drain amylase was measured post-operatively to establish the primary end point of POPF. These were graded A (biochemical) or B and C (clinically relevant, CR-POPF). Secondary endpoints included: Entry in adjuvant therapy, hospital stay, mortality and survival. Overall survival was estimated using the method of Kaplan Meier and defined as the time from randomisation until death by any cause with alive patients censored at the end of study date. Results: Between May 5 2015 and August 7 2017, 238 patients were randomized, 2 patients withdrew, leaving 236 patients for analysis (112 BA, 124 CWA). Median age was 70 years, 63% were men. Median time from diagnosis to randomization (surgery) was 33 days for both arms. In the BA arm there were 28 POPF’s (15-A, 10-B and 3-C) and 32 in the CWA arm (18-A, 12-B and 2-C), p = 0.887. In total 27 patients (11.4%) developed a CR-POPF, BA 13 (5.5%), CWA 14 (5.9%), p = 0.857. 75% of eligible patients entered chemotherapy, with a median (IQR) time to the start treatment of 2.55 (2.27, 3.15) months for the BA group and 2.87 (2.56, 3.75) for the CWA group. Median hospital stay (IQR) in days was 13 (10-24) for BA and 14.5 (10-22) for CWA, p = 0.232. The overall surgical related mortally at 90 days was 1.7%. 44 study deaths were observed, 35 were due to disease progression (BA 19, CWA 16). A hazard ratio (95% CI) of 0.72 (0.4, 1.311) shows better, but not statistically significant survival for the CWA group. Conclusions: This is the largest surgical trial ever conducted comparing these techniques and there was no significant difference in the POPF rate between the BA and CWA anastomoses. In a UK population the clinically relevant POPF rate is 11% and 75% of eligible patients enter chemotherapy. Clinical trial information: ISRCTN52263879 .
妊娠合并糖尿病对母儿的影响
Authors: 张眉花, 杨慧霞
Journal: BMJ (2005)

妊娠合并糖尿病[包括孕前糖尿病以及妊娠糖尿病(GDM)]会导致母儿并发症的增加,随着人们对其诊断、处置等方面水平的提高,母儿结局已得到明显改善.但在我国大部分中、小城市以及广大农村还没有进行GDM的筛查及诊断,所以,目前迫在眉睫的问题是让更多的医务工作者深刻认识GDM对母儿的近、远期影响,以利于GDM筛查的推广,从而减轻该病对母儿的危害,也能减少GDM将来发展成2型糖尿病的几率。
Interdisciplinary family doctor team building and its management in urban community health service: perspectives from primary health workers
Authors: Delu Yin, Tao Yin, Qianqian Xin
Journal: BMJ (2017)

Objective
To survey the perspectives from primary health workers on the building and management of interdisciplinary family doctor team in urban community health service.


Methods
Primary health workers from 24 community health centers of 14 provinces were selected to participate in a questionnaire survey on March 2016. The attitude and satisfaction of participants with interdisciplinary family doctor team in urban community health setting were surveyed and analyzed.


Results
There were 765 questionnaires were distributed and 738 valid ones were returned with a retrieve rate of 96.5%. The survey showed that 70.73%(522/738)of participants supported the interdisciplinary family doctor teamwork, while the overall satisfaction with items regarding its building and management was 48.61% (2 870/5 904). Participants were mostly dissatisfied with performance appraisal and incentive mechanism (32.25%), autonomy of team (40.92%), job division of team members (44.44%) and rationality of professional allocation in the team (48.78%). There were significant differences in overall satisfaction rate among primary health workers in different positions and from different regions (χ2=176.86 and 57.17, both P<0.05). The overall satisfaction of participants in western regions was only 35.65% (636/1 784) and that of public health workers was 43.91% (534/1 216).


Conclusion
Currently, the building and management of interdisciplinary family doctor team in urban community health service are in a initial stage, although its importance has been recognized. Team composition, responsibility of various team members and effective incentive mechanism should be further improved, and more attention should be paid to western regions and for public health workers.


Key words: 
General practitioner; Community health service; Evaluation studies